Objective To investigate the clinical efficacy and safety of Omalizumab in patients with chronic urticaria.Methods Eighty patients with chronic urticaria treated in Zaozhuang Dermatology and Venereal Disease Prevention and Control Hospital from March 2020 to November 2022 were selected as the research objects,and they were divided into ref-erence group and study group,with 40 cases in each group.The reference group was treated with Desloratadine Citrate.The study group were treated with Desloratadine Citrate plus Omazumab.The total effective rate of clinical treatment,clinical symptom score,serological index level,immune function related index and total incidence of adverse reactions were com-pared between the two groups.Results The total effective rate of drug therapy in the study group was higher than that in the reference group,and the difference was statistically significant(P＜0.05).After treatment,the clinical symptom score of the study group was lower than that of the reference group,and the difference was statistically significant(P＜0.05).After treat-ment,interleukin-4 and immunity globulin-E in the study group were lower than those in the reference group,and interfer-on was higher than those in the reference group,with statistical significances(P＜0.05).After treatment,T helper cells(Th)17/regulatory cells(Treg)and Th1/Th2 in the study group were lower than those in the reference group,and the differences were statistically significant(P＜0.05).There was no significant difference in the total incidence of adverse reactions be-tween the two groups(P＞0.05).Conclusion During the treatment of patients with chronic urticaria,the effective application of Omalizumab therapy can effectively improve the therapeutic effect,ensure the safety,and effectively improve the serologi-cal indicators and immune function indicators.
OmazumabChronic urticariaCurative effectClinical safetySerological indexImmune function index
维普
万方数据
